Proclara Obtains U.S. Patents for Technology Targeting Protein-misfolding Disorders Such as Alzheimer’s

Proclara Obtains U.S. Patents for Technology Targeting Protein-misfolding Disorders Such as Alzheimer’s
Proclara Biosciences has announced two additional patents in its effort to develop therapies for neurodegenerative diseases such as Alzheimer’s that have been linked to protein misfolding. A key step in the biotech company's approach  to treating these diseases was discovering a protein motif which recognizes that several toxic misfolded proteins, including Aβ, tau and a-synuclein, share a common amyloid fold. The proprietary motif is called the General Amyloid Interaction Motif (GAIM). Proclara's therapies use GAIM to target the common amyloid fold. The goal is to prevent misfolded proteins from forming and, if they have, to block cells' transmission of proteins that are toxic. The company’s lead development candidate, a GAIM-Ig fusion protein known as NPT088, is being evaluated as a treatment of Alzheimer’s in a Phase 1b clinical trial. The patents that the U.S. Patent and Trademark Office issued to Proclara (9493515 and 9493516) cover agents and compositions aimed at detecting amyloid, reducing amyloid formation and promoting the disintegration of amyloid protein. They are valid until 2034. The patents also cover second- and third-gener
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *